AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback.

Although seemingly more convenient, idraparinux is potentially unsafe in cancer patients due to its long half-life of approximately 4 days and the lack of an available antidote for reversal of the ...

A variety of antidotes have been reported to treat SSRI-induced sexual dysfunction effectively; however, virtually all the data on these agents are derived from open case reports and case series.